

Title: US-10-049-967E-42_COPY_142_206
Perfect score: 65
Sequence: 1 RENEMDENLEQVSGIIGNLR.....SNKTRIDEANQRATKMLGSG
65

RESULT 5

AAW30103

ID AAW30103 standard; peptide; 206 AA.

XX

AC AAW30103;

XX

DT 06-APR-1998 (first entry)

XX

DE Synaptosomal associated protein.

XX

KW Neurotransmitter secretion; inhibitor; neuronal cell; synaptic vesicle;

KW excitation-secretory uncoupling peptide; catecholamine secretion;

KW bovine chromaffin cell; Clostridium toxin; muscle spasticity reduction;

KW synaptosomal associated protein; SNAP-25.

XX

OS Homo sapiens.

XX

PN WO9734620-A1.

XX

PD 25-SEP-1997.

XX

PF 18-MAR-1997; 97WO-US004393.

XX

PR 18-MAR-1996; 96US-0013599P.

XX

PA (REGC) UNIV CALIFORNIA.

XX

PI Montal M;

XX

DR WPI; 1997-479986/44.

XX

PT Excitation-secretory uncoupling peptide(s) for inhibiting

PT neuro:transmitter release - used particularly for treating muscle

PT spasticity, and for delivering drugs specifically to neural cells.

XX

PS Disclosure; Page 27-28; 61pp; English.

XX

CC This sequence represents the human 25 kD synaptosomal associated protein

CC (SNAP-25), which is an inhibitory agent of the invention. The agents of

CC the invention inhibit secretion of neurotransmitter from neuronal cells

CC and is an excitation-secretory uncoupling peptide (I) of at least 20

CC amino acids (aa) all of which correspond substantially to any one of
CC AAW30097-W30102, or more generally any (I) that inhibits 50% of
CC catecholamine secretion from bovine chromaffin cells at a concentration
CC of 10 microM, especially 0.25 microM, or less. (I) are used, as a
CC replacement for Clostridium toxin, to inhibit release of
CC neurotransmitters from synaptic vesicles, specifically for reducing
CC muscle spasticity. Also (I) may be labelled to allow in vivo imaging of
CC intracellular distribution of (I). Compounds for delivering the drug to
CC neural cells provide targeted drug delivery, e.g. of substance P to brain
CC tumours for induction of apoptosis. Unlike the neurotoxins, (I) are not
CC toxic or immunogenic and are more readily available. Their therapeutic
CC effect lasts for several days or weeks, so lower doses or less frequent
CC treatments are required

XX

SQ Sequence 206 AA;

Query Match 100.0%; Score 65; DB 2; Length 206;
Best Local Similarity 100.0%; Pred. No. 4.3e-59;
Matches 65; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1
RENEMDENLEQVSGIIGNLRHMAIDMGNEIDTQNRQIDRIMEKADSNKTRIDEA
NQRATK 60

|||||

Db 142
RENEMDENLEQVSGIIGNLRHMAIDMGNEIDTQNRQIDRIMEKADSNKTRIDEA
NQRATK 201

Qy 61 MLGSG 65
|||||
Db 202 MLGSG 206

Title: US-10-049-967E-42
Perfect score: 1052
Sequence: 1
MAEDADMRNELEEMQRRADQ.....SNKTRIDEANQRATKMLGSG 206

RESULT 7
AAW30103
ID AAW30103 standard; peptide; 206 AA.
XX
AC AAW30103;
XX
DT 06-APR-1998 (first entry)

XX
DE Synaptosomal associated protein.
XX
KW Neurotransmitter secretion; inhibitor; neuronal cell; synaptic vesicle;
KW excitation-secretory uncoupling peptide; catecholamine secretion;
KW bovine chromaffin cell; Clostridium toxin; muscle spasticity reduction;
KW synaptosomal associated protein; SNAP-25.
XX
OS Homo sapiens.
XX
PN WO9734620-A1.
XX
PD 25-SEP-1997.
XX
PF 18-MAR-1997; 97WO-US004393.
XX
PR 18-MAR-1996; 96US-0013599P.
XX
PA (REGC) UNIV CALIFORNIA.
XX
PI Montal M;
XX
DR WPI; 1997-479986/44.
XX
PT Excitation-secretory uncoupling peptide(s) for inhibiting
PT neuro:transmitter release - used particularly for treating muscle
PT spasticity, and for delivering drugs specifically to neural cells.
XX
PS Disclosure; Page 27-28; 61pp; English.
XX
CC This sequence represents the human 25 kD synaptosomal associated protein
CC (SNAP-25), which is an inhibitory agent of the invention. The agents of
CC the invention inhibit secretion of neurotransmitter from neuronal cells
CC and is an excitation-secretory uncoupling peptide (I) of at least 20
CC amino acids (aa) all of which correspond substantially to any one of
CC AAW30097-W30102, or more generally any (I) that inhibits 50% of
CC catecholamine secretion from bovine chromaffin cells at a concentration
CC of 10 microM, especially 0.25 microM, or less. (I) are used, as a
CC replacement for Clostridium toxin, to inhibit release of
CC neurotransmitters from synaptic vesicles, specifically for reducing
CC muscle spasticity. Also (I) may be labelled to allow in vivo imaging of
CC intracellular distribution of (I). Compounds for delivering the drug to
CC neural cells provide targeted drug delivery, e.g. of substance P to brain
CC tumours for induction of apoptosis. Unlike the neurotoxins, (I) are not
CC toxic or immunogenic and are more readily available. Their therapeutic
CC effect lasts for several days or weeks, so lower doses or less frequent

XX

SQ Sequence 206 AA;

Query Match 95.4%; Score 1004; DB 2; Length 206;

Best Local Similarity 95.6%; Pred. No. 4.1e-86;

Matches 197; Conservative 5; Mismatches 4; Indels 0; Gaps 0;

Qy 1

MAEDADMNRNELEEMQRRADQLADESLESTRMLQLVEESKDAGIRTLVMLDEQ
GEQLDRV 60

|||||:|

Db 1

MAEDADM RNELEEMQRRADQLADESLESTRMLQLVEESKDAGIRTLVMLDEQ
GEQLERI 60

Qy 61

EEGMNHINQDMKEAEKNLKD LGKCCGLFICPCNKLKSSDAYKKAWGNNQDGV
VASQPARV 120

[illegible]

Db 61

EEGMDQINKDMKEAEKNLTDLGKFCGLCVCPCNKLKSSDAYKKAWGNNQDGV
VASQPARV 120

Qy 121

VDEREQMAISGGFIRRV¹TNDARENEMDENLEQVSGIIGNLRH²MALDMGNEIDTQ
NRQIDR 180

Db 121

VDEREQMAISGGFIRRV TNDARENEMDENLEQVSGIIGNLRHMA LDMGNEIDTQ
NRQIDR 180

Qy 181 IMEKADSNKTRIDEANQRATKMLGSG 206

Db 181 IMEKADSNKTRIDEANQRATKMLGSG 206